Nivolumab Plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC): 3-Year Follow-Up From the Phase 3 CheckMate 9 ER Trial (vol 41, pg 603, 2023)

被引：1
作者：
Motzer, Robert J.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 21期
关键词：
D O I：
10.1200/JCO.23.00901
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3767 / 3767
页数：1
相关论文
共 50 条
[31]   Partitioned overall survival: Comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC) [J].
Mantia, Charlene ;
Jegede, Opeyemi ;
Viray, Hollis ;
Atkins, Michael B. ;
Rosenblatt, Lisa ;
Yin, Xin ;
McDermott, David F. ;
Regan, Meredith M. .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[32]   Increasing combination possibilities for first-line treatment of metastatic clear cell renal cell carcinoma with nivolumab plus cabozantinib Results of the CheckMate-9ER trial [J].
Oing, Christoph ;
Bokemeyer, Carsten .
ONKOLOGE, 2021, 27 (02) :168-171
[33]   Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (vol 20, pg 1370, 2019) [J].
Motzer, R. J. ;
Rini, B., I ;
McDermott, D. F. .
LANCET ONCOLOGY, 2020, 21 (06) :E304-E304
[34]   Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (vol 20, pg 1370, 2019) [J].
Motzer, R. J. ;
Rini, B., I ;
McDermott, D. F. .
LANCET ONCOLOGY, 2020, 21 (11) :E518-E518
[35]   Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (vol 20, pg 1370, 2019) [J].
Motzer, R. J. ;
Rini, B., I ;
McDermott, D. F. .
LANCET ONCOLOGY, 2019, 20 (10) :E559-E559
[36]   JAVELIN renal 101: a phase 3 study of avelumab in combination with axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC) [J].
Choueiri, Toni K. ;
Rini, Brian I. ;
Cosgriff, Thomas ;
Miyake, Hideaki ;
Vogelzang, Nicholas J. ;
Kannourakis, George ;
Mariani, Mariangela ;
Chiruzzi, Chiara ;
Albiges, Laurence ;
Haanen, John B. ;
Larkin, James ;
Atkins, Michael B. ;
Schmidinger, Manuela ;
Magazzu, Domenico ;
Di Pietro, Alessandra ;
Motzer, Robert J. .
BJU INTERNATIONAL, 2016, 118 :29-30
[37]   Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States [J].
Li, SiNi ;
Li, JianHe ;
Peng, LiuBao ;
Li, YaMin ;
Wan, XiaoMin .
FRONTIERS IN PHARMACOLOGY, 2021, 12
[38]   JAVELIN renal 101: A randomized, phase III study of avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC) [J].
Motzer, R. J. ;
Penkov, K. ;
Haanen, J. B. A. G. ;
Rini, B. I. ;
Albiges, L. ;
Campbell, M. T. ;
Kollmannsberger, C. K. ;
Negrier, S. ;
Uemura, M. ;
Lee, J. L. ;
Gurney, H. ;
Berger, R. ;
Schmidinger, M. ;
Larkin, J. ;
Atkins, M. B. ;
Wang, J. ;
Robbins, P. B. ;
Chudnovsky, A. ;
Di Pietro, A. ;
Choueiri, T. K. .
ANNALS OF ONCOLOGY, 2018, 29 :724-724
[39]   Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO plus IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214. [J].
Tannir, Nizar M. ;
Motzer, Robert J. ;
Albiges, Laurence ;
Plimack, Elizabeth R. ;
George, Saby ;
Powles, Thomas ;
Donskov, Frede ;
Rini, Brian, I ;
Grunwald, Viktor ;
Hammers, Hans J. ;
Choueiri, Toni K. ;
Gurney, Howard ;
Tykodi, Scott S. ;
Porta, Camillo ;
Burotto, Mauricio ;
Tomita, Yoshihiko ;
Lee, Chung-Wei ;
Tang, Chad ;
McDermott, David F. ;
McKay, Rana R. .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[40]   Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study [J].
Tomita, Yoshihiko ;
Fukasawa, Satoshi ;
Shinohara, Nobuo ;
Kitamura, Hiroshi ;
Oya, Mototsugu ;
Eto, Masatoshi ;
Tanabe, Kazunari ;
Saito, Mitsuru ;
Kimura, Go ;
Yonese, Junji ;
Yao, Masahiro ;
Uemura, Hirotsugu .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (06) :506-514
12345